Taken together, although the field studying the role of IL4I1 in cancer immune escape is still in its relative infancy compared to that of IDO1, the pharmacological targeting of IL4I1 offers new prospects for the treatment of cancer patients. The gene discussed is IL4I1; the disease is cancer.